A statistically significant difference was found in the expression of MGMT methylation according to the grade of the tumour (75% patients with grade III vs. 34% with grade IV).28 We did not find differences in any of the analysed fields of cognitive functioning and also not in the number of tests in which patients achieved an impaired result. The gene discussed is MGMT; the disease is neoplasm.